Results 261 to 270 of about 108,384 (342)

Combination therapy including dupilumab, omalizumab, and mycophenolate mofetil for refractory bullous pemphigoid. [PDF]

JAAD Case Rep
Ratnarajah K, Arès S, Kechichian E, Fernandes CL.   +3 more
europepmc   +1 more source

Molecular biology of the mouse Q region [PDF]

, 1987
A. Eastman O'Neill, A. Winoto, A.-M. Lew, A.L. Mellor, A.L. Mellor, A.L. Mellor, C. Jaulin, C.G. Miyada, D. Cosman, D. Cosman, D. Stephan, D.A. Fisher, D.H. Schulze, D.S. Straus, E.H. Weiss, E.H. Weiss, E.H. Weiss, Elisabeth H. Weiss, F. Bregegere, I. Stroynowski, J. Geliebter, J. Klein, J. Michaelson, J. Stroynowski, J.H. Rogers, J.H. Rogers, J.J. Devlin, J.J. Devlin, J.L. Lalanne, J.L. Lalanne, L. Flaherty, L. Flaherty, L.R. Pease, M. Kress, M. Steinmetz, M. Steinmetz, R.A. Flavell, R.A. Flavell, R.S. Goodenow, S.G. Nathenson, W.L. Maloy, Y. Obata   +41 more
core   +1 more source

The Therapeutic Potential of Farm Dust Extracts in a Mouse Model of Eosinophilic Inflammation

Allergy, EarlyView.
Farm dust extract (FDE) treatment reduces airway eosinophilia, mucus overproduction, and MHC‐II expression on DCs, limiting antigen presentation and Th2 inflammation. It increases PD‐L1 on DCs, promoting T cell deactivation. Additionally, FDE enhances Tregs and upregulates CTLA‐4, reinforcing suppression.
Rabia Ülkü Korkmaz, Jimmy Omony, Xiaomei Tan, Markus Klotz, Guilherme Dragunas, Sirui Chen, Soni Shankhwar, Zeynep Ertüz, Christoph Müller, Mohab Ragab, Aicha Jeridi, Romina Augustin, Janna Nawroth, Theodore S. Kapellos, Bettina Rankl, Ali Önder Yildirim, Erika von Mutius   +16 more
wiley   +1 more source

Investigation of the protective efficacy of Caesalpinia sappan and spirulina against ethanol-induced experimental rat gastritis model. [PDF]

Acta Cir Bras
Oruç İ, Karakoç Z, Akduman F, Oruç Z, Baksi N, Ketani MA.   +5 more
europepmc   +1 more source

Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains

, 2001
Kenneth A. Frauwirth, Nilabh Shastri
openalex   +1 more source

Dynamic Regulation of Collagens, Proteases, Their Inhibitors, and Cell Death in Experimental Asthma in Mice

Allergy, EarlyView.
This study investigates airway remodeling in acute and chronic experimental asthma models induced by house dust mite extract to elucidate inflammatory and structural changes. Two acute T2‐low models demonstrated pronounced airway inflammation characterized by goblet cell hyperplasia, collagen deposition, and significant upregulation of extracellular ...
Marlena Tynecka, Agnieszka Tarasik, Bartosz Hanczaruk, Adrian Janucik, Krystian Czolpinski, Alicja Walewska, Arkadiusz Zbikowski, Anna Zeller, Agnieszka Kulczynska‐Przybik, Magdalena Niemira, Joanna Reszec‐Gielazyn, Barbara Mroczko, Adam Kretowski, Cezmi A. Akdis, Milena Sokolowska, Marcin Moniuszko, Cagatay Karaaslan, Andrzej Eljaszewicz   +17 more
wiley   +1 more source

MAPPs assays for non-clinical immunogenicity risk assessment: best practices recommended by the European immunogenicity platform. [PDF]

Front Immunol
Karle AC, Kopp KL, Seward RJ, Tourdot S, Ackaert C, Gutknecht M, Cloake E, Smith N, Ducret A.   +8 more
europepmc   +1 more source

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy

British Journal of Pharmacology, EarlyView.
Abstract Contemporary strategies in cancer immunotherapy, despite remarkable success, remain constrained by inherent limitations such as suboptimal patient responses, the emergence of drug resistance, and the manifestation of pronounced adverse effects. Consequently, the need for alternative strategies for immunotherapy becomes clear.
Zihan Qu, Jiajun Dong, Zhong‐Yin Zhang
wiley   +1 more source

Autophagy Differentially Influences Toll-like Receptor 9 and B Cell-Receptor-Mediated B Cell Expansion, Expression of Major Histocompatibility Class II Proteins, and Antigenic Peptide Presentation. [PDF]

Int J Mol Sci
Peddaboina C, Iannucci J, Tobin RP, Shapiro LA, Newell Rogers MK.   +4 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source